Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine - PubMed (original) (raw)

. 2007 Nov 19;25(47):8067-76.

doi: 10.1016/j.vaccine.2007.09.012. Epub 2007 Sep 20.

Affiliations

• PMID: 17919786
• DOI: 10.1016/j.vaccine.2007.09.012

Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine

Sang-Uk Seo et al. Vaccine. 2007.

Abstract

In this study, we evaluated a live attenuated influenza vaccine (X-31 ca, H3N2) as a fast-acting prophylaxis against both heterologous (A/New Caledonia/99, H1N1) and heterotypic (B/Shangdong/97, influenza B) infection. An immediate and broad-spectrum protection was achieved in the absence of specific antibody responses. Vaccination immediately prior to challenge resulted in the generation of a significant pool of reassortant virus between the vaccine and virulent strains suggesting that the acquisition of attenuating gene(s) from the live vaccine contributes to the attenuation of virulence. Vaccination resulted in an immediate release of the antiviral IFN-alpha response and pro-inflammatory cytokines. In addition, it was determined that agonists for TLR 3 and TLR 7 provided early protection. Thus, our results suggest that innate immune responses and genetic interference may play a role, independently and synergistically, in early protection by live influenza vaccination. The broad-spectrum and immediate protection provided by live attenuated influenza vaccine may offer a prompt measure for minimizing the initial spread of virus and mitigating the impact of unexpected influenza outbreaks.

PubMed Disclaimer

Similar articles

• A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
  Xie H, Liu TM, Lu X, Wu Z, Belser JA, Katz JM, Tumpey TM, Ye Z. Xie H, et al. J Infect Dis. 2009 Dec 15;200(12):1874-83. doi: 10.1086/648405. J Infect Dis. 2009. PMID: 19909080
• Development and characterization of a live attenuated influenza B virus vaccine candidate.
  Seo SU, Byun YH, Lee EY, Jung EJ, Jang YH, Kim HA, Ha SH, Lee KH, Seong BL. Seo SU, et al. Vaccine. 2008 Feb 13;26(7):874-81. doi: 10.1016/j.vaccine.2007.12.022. Epub 2008 Jan 7. Vaccine. 2008. PMID: 18207290
• Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
  Du N, Li W, Li Y, Liu S, Sui Y, Qu Z, Wang Y, Du Y, Xu B. Du N, et al. Vaccine. 2008 Jun 2;26(23):2912-8. doi: 10.1016/j.vaccine.2008.03.048. Epub 2008 Apr 11. Vaccine. 2008. PMID: 18448208
• Influenza vaccine 2008-2009.
  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2008 Oct 6;50(1296):77-9. Med Lett Drugs Ther. 2008. PMID: 18833032 Review.
• Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?
  Skowronski DM, Tweed SA, De Serres G. Skowronski DM, et al. J Infect Dis. 2008 Feb 15;197(4):490-502. doi: 10.1086/524146. J Infect Dis. 2008. PMID: 18275271 Review.

Cited by

• Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.
  McElhaney JE. McElhaney JE. Aging health. 2008 Dec 1;4(6):603-613. doi: 10.2217/1745509X.4.6.603. Aging health. 2008. PMID: 20011611 Free PMC article.
• Leveraging Beneficial Off-Target Effects of Live-Attenuated Rotavirus Vaccines.
  Benedicto-Matambo P, Bines JE, Malamba-Banda C, Shawa IT, Barnes K, Kamng'ona AW, Hungerford D, Jambo KC, Iturriza-Gomara M, Cunliffe NA, Flanagan KL, Jere KC. Benedicto-Matambo P, et al. Vaccines (Basel). 2022 Mar 10;10(3):418. doi: 10.3390/vaccines10030418. Vaccines (Basel). 2022. PMID: 35335050 Free PMC article. Review.
• Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice.
  Lorenzo ME, Hodgson A, Robinson DP, Kaplan JB, Pekosz A, Klein SL. Lorenzo ME, et al. Vaccine. 2011 Nov 15;29(49):9246-55. doi: 10.1016/j.vaccine.2011.09.110. Epub 2011 Oct 6. Vaccine. 2011. PMID: 21983155 Free PMC article.
• Reverse genetic platform for inactivated and live-attenuated influenza vaccine.
  Jung EJ, Lee KH, Seong BL. Jung EJ, et al. Exp Mol Med. 2010 Feb 28;42(2):116-21. doi: 10.3858/emm.2010.42.2.013. Exp Mol Med. 2010. PMID: 20054235 Free PMC article.
• Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses.
  Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y. Shinya K, et al. Virol J. 2011 Mar 4;8:97. doi: 10.1186/1743-422X-8-97. Virol J. 2011. PMID: 21375734 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information